# Give immunotherapy in the morning

Source: https://onco.cc/ideas/idea-chronotherapy-immunotherapy/  
OnCo record `idea-chronotherapy-immunotherapy` (Idea). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Several studies found patients infused with checkpoint inhibitors earlier in the day lived longer. If a randomised trial confirms it, it is a free improvement available everywhere tomorrow.

## Summary

This idea proposes giving immunotherapy in the morning: patients infused with checkpoint inhibitors earlier in the day lived longer in several studies, and a randomised trial could confirm a free improvement. Retrospective cohorts (Lancet Oncology 2021 and follow-ups) and the small randomised MEMOIR signal associate morning infusions with better survival, plausibly through circadian T-cell trafficking (Circadian control pathway). The hypothesis is that infusing Immune checkpoint inhibitors against PD-1 before midday improves overall survival compared with afternoon infusions, backed by consistent cohort data and mouse immunology. The test is a large pragmatic randomised trial of morning against afternoon infusion in first-line PD-1 therapy for Non-small-cell lung cancer and Melanoma.

## Fields

- Kind: Idea
- Last checked: 2026-09-08
- Tags: mechanism; open-question
- Hypothesis: Scheduling checkpoint-inhibitor infusions before midday improves overall survival compared with afternoon infusions, with an effect size large enough to change infusion-unit scheduling.
- Rationale: Consistent direction across cohorts, mechanistic backing in mouse immunology, zero drug cost, and trivial implementation.
- Proposed test: Large pragmatic randomised trial of morning vs afternoon infusion in first-line PD-1 therapy for NSCLC and melanoma, endpoint OS; embedded immune-trafficking biomarkers.
- Maturity: early-clinical

## Sources

- Qian et al., Effect of immunotherapy time-of-day infusion on overall survival in advanced melanoma (Lancet Oncology 2021): https://doi.org/10.1016/S1470-2045(21)00546-5

## Connected records

- cancers: [Melanoma](https://onco.cc/cancers/melanoma/), [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/)
- technologies: [Immune checkpoint inhibitors](https://onco.cc/technologies/checkpoint-inhibitor/), [Sleep and circadian interventions in cancer](https://onco.cc/technologies/sleep-circadian-interventions/)
- targets: [PD-1](https://onco.cc/targets/pd1/)
- institutions: [Gustave Roussy](https://onco.cc/institutions/gustave-roussy/), [Memorial Sloan Kettering Cancer Center](https://onco.cc/institutions/mskcc/)
- pathways: [Circadian control](https://onco.cc/pathways/circadian-control/), [PD-1 / PD-L1 immune checkpoint & T-cell activation](https://onco.cc/pathways/pd1-checkpoint/)
- trials: [CheckMate 227](https://onco.cc/trials/checkmate-227/), [CheckMate 915](https://onco.cc/trials/checkmate-915/), [Fianlimab + cemiplimab phase 3 (first-line melanoma)](https://onco.cc/trials/fianlimab-phase3-melanoma/), [KEYNOTE-042](https://onco.cc/trials/keynote-042/), [RELATIVITY-098](https://onco.cc/trials/relativity-098/)
- key papers: [CTLA-4 and PD-1 Pathways: Similarities, Differences, and Implications of Their Inhibition](https://onco.cc/key-papers/paper-pd-1-nsclc-am-j-clin-oncol-2016/), [Effect of immunotherapy time-of-day infusion on overall survival among patients with advanced melanoma in the USA (MEMOIR): a propensity score-matched analysis of a single-centre, longitudinal study](https://onco.cc/key-papers/paper-qian-lancet-oncol/), [STK11/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS -Mutant Lung Adenocarcinoma](https://onco.cc/key-papers/paper-kras-nsclc-cancer-discov-2018/), [Topalian 2012: the first large trial of a PD-1 antibody shows durable responses across melanoma, lung and kidney cancer](https://onco.cc/key-papers/paper-topalian-anti-pd1-nejm-2012/)
- ideas: [Treat insomnia in survivors and measure whether the cancer notices](https://onco.cc/ideas/idea-nl-sleep-circadian-survivorship-rct/)

---
JSON: https://onco.cc/api/v1/entities/idea-chronotherapy-immunotherapy.json